The companies have agreed to join their respective technologies into an integrated product for artificial intelligence-based prostate cancer diagnosis.
The firms said that Abcam will be the preferred supplier of gold nanoparticles and custom conjugation reagents and services for Abingdon's lateral flow assays.
The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.
The deal is aimed at providing technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.